Lv4
420 积分 2022-04-01 加入
Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development
17小时前
已完结
Head and Neck Cancer
21天前
已完结
Head and neck squamous cell carcinoma
21天前
已完结
Head and Neck Cancer
21天前
已完结
Oncolytic viruses: a new class of immunotherapy drugs
21天前
已完结
Elements of cancer immunity and the cancer–immune set point
21天前
已完结
Cancer immunotherapy using checkpoint blockade
21天前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
22天前
已完结
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
22天前
已完结
The future of immune checkpoint therapy
22天前
已完结
皖公网安备34019202002308
